精准医学背景下肺癌化疗的新角度和新思考

发布时间：2018-05-03 06:29

本文选题：精准医学 + 肺癌　；参考：《医学研究生学报》2017年11期

【摘要】：以培美曲塞二钠对肺鳞癌及非鳞癌的疗效差异为起点,开启了精准化疗时代。为进一步提高化疗的精度,一方面,研究靶向治疗的原发性耐药机制,找到化疗优于靶向治疗的受益人群;另一方面,探索预测化疗预后的基因或机制,精准使用化疗,循环肿瘤细胞(CTC)、循环肿瘤DNA(cf-DNA或ct-DNA)人源肿瘤动物模型(PDX)可能成为未来预测化疗疗效的研究方向;而研发新一代抗体耦联药物,可提高化疗药物的靶向性,降低化疗的不良反应。化疗因其广覆盖的特性,作为治疗基石,与靶向药物(酪氨酸激酶抑制剂或抗血管生成药物)、免疫治疗联用可显著提高疗效。在精准医学时代,肺癌的化疗将获得新的定位。
[Abstract]:Beginning with the difference of efficacy between pemetrexide disodium and non-squamous cell carcinoma of lung, the era of accurate chemotherapy was opened. In order to further improve the accuracy of chemotherapy, on the one hand, we should study the mechanism of primary drug resistance of targeted therapy, and find out that chemotherapy is superior to target therapy. On the other hand, we should explore the gene or mechanism of predicting the prognosis of chemotherapy and use chemotherapy accurately. The human tumor animal model of circulating tumor DNA(cf-DNA or ct-DNA) may become the research direction of predicting the therapeutic effect of chemotherapy in the future, and the development of a new generation of antibody-coupled drugs can improve the targeting of chemotherapeutic drugs and reduce the adverse reactions of chemotherapy. Because of its wide coverage, chemotherapy, as a cornerstone of treatment, combined with targeted drugs (tyrosine kinase inhibitors or antiangiogenic drugs), immunotherapy can significantly improve the efficacy. In the age of precision medicine, chemotherapy for lung cancer will gain a new orientation.
【作者单位】：郑州大学附属肿瘤医院/河南省肿瘤医院呼吸三科河南省肺癌诊疗中心;
【基金】：国家自然科学基金(81272600) 河南省自然科学基金(162300410300) 河南省卫生计生科技创新型人才“51282工程”领军人才(豫卫科[2016]32号) 河南省医学科技攻关计划省部共建项目(201601026) 吴阶平医学基金会临床科研专项资助基金(320.6799.15018) 河南省高校科技创新人才支持计划(18HASTIT044)
【分类号】：R734.2

【相似文献】